Pharma companies in a flux over Trump’s 200% tariff move on generics
India’s $30-billion pharma industry is staring at a fresh challenge after US President Donald Trump announced that generic medicines imported into the US would face tariffs of 100% from Aug 2028 and 200% a year later, unless companies relocate manufacturing to the US.The announcement has significant implications for India, which supplies nearly 47% of generic…